The 49.8% gross margin is a significant outlier versus the trailing four-quarter average of ~44%, indicating that the company is benefiting from both price realization and a favorable product mix, likely driven by the Elkay hydration and filtration lines. Operating margin of 17.4% is near the high end of the 10-quarter range, and the 120 bps EBITDA margin expansion to 27.7% in Q2 2026, as reported, suggests operational leverage is being realized despite flat reported revenue. However, the sustainability of this margin level is questionable given the weak ABI and potential raw material cost volatility; investors should monitor whether this is a new baseline or a temporary peak.

Despite robust margins, ROIC has been stagnant in the 2-3% range over the past ten quarters, which is far below the cost of capital and peer averages. This suggests that the Elkay acquisition has not yet generated the expected returns on invested capital, possibly due to goodwill and amortization from purchase accounting. The low asset turnover of 0.16x, compared to peers, indicates that the company's capital intensity is higher than its asset-light model suggests, likely because of the large intangible base. If management can grow revenue without proportional capital increases, ROIC could improve, but current trends imply a slow compounding of returns.

The CCC has been on an upward trend, from 113 days in Q3 2025 to 132 days in Q2 2026, primarily due to a 25-day increase in days inventory outstanding (DIO) over the same period. This suggests that inventory is accumulating, which could be a response to supply chain disruptions or a sign of weakening end-market demand. DSO has also ticked up to 53 days, while DPO remains relatively stable at 40 days, indicating that ZWS is not extending payables to offset the working capital drain. The negative working capital impact is evident in the cash flow statement, where working capital changes swung to a $26.7M use in Q2 2026. If the ABI weakness translates into slower sales, this inventory buildup could become a drag on cash flow.

While the balance sheet appears conservative with a D/E of 0.33, the D/EBITDA ratio spiked to 9.81x in Q2 2026, up from 5.58x in Q2 2025, which is a significant deterioration. This could be due to a temporary dip in EBITDA or an increase in debt, but the interest coverage of 13.28x remains comfortable, suggesting that debt service is not an immediate concern. However, the elevated D/EBITDA may indicate that the company's earnings power is not as robust as the low D/E suggests, and if EBITDA normalizes, the leverage could become more concerning. Investors should monitor whether this is a one-off or a trend, especially given the company's M&A appetite.

The current ratio of 3.05 and quick ratio of 2.13 indicate that ZWS has more than sufficient short-term assets to cover its liabilities, even if inventory becomes difficult to liquidate. The improvement in the current ratio over the past year suggests that management is deliberately building a liquidity buffer, possibly in anticipation of economic uncertainty. With cash of $365M and minimal debt maturities, the company is well-positioned to weather a cyclical downturn without needing to access capital markets. This fortress-like liquidity also provides flexibility for strategic acquisitions, which aligns with management's history of value-creative M&A.